Under the terms of the option agreement, which was signed in December 2024, Bausch + Lomb has secured the exclusive option to acquire InflammX Therapeutics during an agreed-upon option period based on ...
Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, ...
Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine ...
The following is a summary of “Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy,” published in the January 2025 ...
City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced that it has entered into a strategic collaboration ...
City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...
Keegan Paradis grew up watching his father, Brendon, lose his vision to a condition no one could name. "My wife said, 'Take ...
“Brighter irises and larger pupils elicited greater donations,” noted experts from the Netherlands’ Leiden University in a ...
Optometry professionals have welcomed plans to tackle waiting lists, and highlighted the skills, experience, and equipment of ...
Omega-3 polyunsaturated fatty acids and docosahexaenoic acid appear to be associated with lower age-related macular ...
Harrison, 69, from Lossiemouth, sought help from North East Sensory Services (NESS) after being diagnosed with macular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback